Our Parkinson's Place: FoxFeed Blog: MJFF Scientist Highlights Alpha-synuclein Research Progress in Nature Reviews Drug Discovery

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Thursday, June 29, 2017

FoxFeed Blog: MJFF Scientist Highlights Alpha-synuclein Research Progress in Nature Reviews Drug Discovery

By Kristen Teesdale, June 29, 2017

As researchers search for a therapy to slow or stop Parkinson's disease (PD) progression, alpha-synuclein has emerged as a leading target. This protein clumps in the brains of nearly everyone with Parkinson's and it's the primary component of Lewy bodies, the pathological hallmark of PD. At the current time, five therapies representing varied approaches against alpha-synuclein are in different stages of clinical trial testing.

In an interview for Nature Reviews Drug Discovery, Brian Fiske, PhD, senior vice president of research programs at MJFF, discussed the field's focus on alpha-synuclein. "The real unmet medical need [in Parkinson's] is a treatment that can target the underlying disease mechanism and can slow and ultimately halt the disease process. That's where the excitement around targets like a-synuclein comes from."

Read the full article to learn more about alpha-synuclein and the therapies in testing:

http://www.readcube.com/articles/10.1038/nrd.2017.95?shared_access_token=X_NzUw7vu4_cNX_TEJtn69RgN0jAjWel9jnR3ZoTv0MS9PnCoWe_UuQ5GUohdo8M22W0grgKbbY0Rjxk-Vz1YYT1UTtOMNWc3SksCsfsmTh4xco4oNZrI_E7NGyViQhYjiobKCbl_-7CDRPQM8QAJA%3D%3D

Go to the following web site below and click on:Read the full article to learn more about alpha-synuclein and the therapies in testing:

https://www.michaeljfox.org/foundation/news-detail.php?mjff-scientist-highlights-alpha-synuclein-research-progress-in-nature-reviews-drug-discovery